Pharmgate Animal Health is pleased to announce PRRSGard, an innovative, modified-live vaccine, is available broadly in the U.S. market.
PRRSGard is a 1.0 milliliter, single-dose recombinant chimeric vaccine for porcine reproductive and respiratory syndrome. It features:
- An attenuated, lineage 1 PRRSV strain as a vaccine backbone
- A virulent, contemporary lineage 1 PRRSV field isolate, MN 1-8-4
A non-encoding RNA sequence is inserted into the genome. This unique genetic marker allows diagnostic assay differentiation from "wild-type" virus strains.
Pharmgate Animal Health has worked with researchers and customers to test PRRSGard beyond research needed for licensing. Trials show that PRRSGard has low vaccine virus shed and spread, broad cross-strain immunity, and reduced lung lesions and viremia following a challenge. It has been shown to reduce performance loss from pneumonia associated with PRRSV in growing pigs.
PRRSV costs the U.S. pork industry an estimated $664 million annually. This figure has been hard to reduce, partly due the continued evolution of PRRSV.
"PRRSV continues to be a costly disease and difficult to control in herds," says Jeff OKones, technical services veterinarian with Pharmgate Animal Health. "PRRSGard is an innovative new tool created by Pharmgate's product development team for veterinarians and producers to utilize in their herd health protocols to optimize pig performance in the face of PRRSV."
Founded in 2008, Pharmgate Animal Health is headquartered in Wilmington, N.C. and provides innovative and high-quality products that help the livestock industry optimize animal health, efficiency and production. The company's pharmaceutical production facilities are in Omaha, Neb. with vaccine research and manufacturing operations based in St. Paul, Minn.